SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Boston Scientific Corporation Common Stock and Sets a Lead Plaintiff Deadline of May 4, 2026

Core Viewpoint - A class action lawsuit has been initiated against Boston Scientific Corporation due to allegations of misleading statements regarding the company's U.S. electrophysiology (EP) segment, which led to a significant drop in stock price following disappointing financial results and guidance [1][2][3]. Group 1: Lawsuit Details - The lawsuit, John Rudolph Troike v. Boston Scientific Corporation, was filed in the United States District Court for the District of Massachusetts, targeting individuals who purchased Boston Scientific common stock between July 23, 2025, and February 3, 2026 [1]. - The complaint alleges that Boston Scientific's management provided overly optimistic statements while concealing the unsustainable growth rate of the U.S. EP segment, which contributed to a net income miss and poor guidance for the first half of fiscal 2026 [2]. Group 2: Financial Performance - On February 4, 2026, Boston Scientific reported disappointing fourth quarter and full year 2025 results, particularly in U.S. EP sales, and issued guidance for fiscal 2026 that was significantly below market expectations [3]. - The company's stock price plummeted from $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026, marking a decline of approximately 17.6% in just one day [3]. Group 3: Investor Actions - Investors who suffered losses in Boston Scientific's common stock are encouraged to step forward before the May 4, 2026 deadline to request appointment as lead plaintiff in the lawsuit [4]. - The law firm Levi & Korsinsky emphasizes its commitment to securing compensation for investors affected by corporate misrepresentations [4].